Aequus Pharmaceuticals (TSE:AQS) has released an update.
Aequus Pharmaceuticals responds to the Canadian shortage of 0.03% bimatoprost, a key glaucoma treatment, by ramping up supply of its preservative-free Zimed® PF eye drops. The company anticipates increased demand and sales revenue for its unique multi-dose product in the wake of this shortage. Aequus is focused on ensuring continuous patient access to this essential medication.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.
